The UK will remain a member of the Paris Convention as adopted in 1883, which underpins the priority filing system around the globe. Further detailed information on matters of Intellectual Property can be identified in the UK and EU Agreement...
Conference 9-10 May 2024
"Development of scientific research and innovation at Thracian University in the service of health and sustainable well-being"
THRACIAN UNIVERSITY - STARA ZAGORA, BULGARIA
Georgia, has completed all the requirements for entering into force the Agreement with the European Patent Organisation on validation of European Patents (Validation Agreement). The Georgian Parliament has adopted corresponding amendments to the Patent Law of Georgia.
The UK will remain a member of the Paris Convention as adopted in 1883, which underpins the priority filing system around the globe. Further detailed information on matters of Intellectual Property can be identified in the UK and EU Agreement...
Transfer of ownership of a European patent (application) before the European Patent Office (EPO) is not an easy task. Evidence of the transfer must be provided in the form of a written document (such as an assignment document) signed by all parties.
The status of trade secrets as an item of property is not clear. Most practitioners share the view that trade secrets are not property. Strictly speaking, trade secrets in the UK may be protected either through a breach of contract action or alternatively by a statutory trade secrets action.
The first U.S. patent was issued in 1790 to Samuel Hopkins for a process of making potash, an ingredient used in fertilizer and soap production. Patents have been sparking innovation for centuries!
Patent infringement exemptions in the UK to life sciences products are confusing which is not surprising considering that there are three reference points:
Today, 1st June 2023 marks a historical milestone for the patent system across Europe and therefore also for the European Patent Attorney (EPA) profession.
We are delighted to announce that European Patent Attorney, Dr Stoyan Radkov is now a fully registered representative before the Unified Patent Court (UPC).
On 17 February 2023, Germany deposited its instrument of ratification of the Unified Patent Court Agreement (UPCA) with the Council of the European Union (EU). The Unified Patent Court (UPC) will therefore start on 01 June 2023..
Databases are valuable commercial IP assets which businesses are increasingly seeking to exploit. Given their inherent and financial value, together with the money and time invested in their creation.
A new patent system is coming to Europe and there are unique advantages to using a UK based patent attorney firm. Please watch the animation and use our London patent firm for representation before the Unified Patent Court:
Once Germany ratifies, the countries in which a UP will have effect are Austria, Belgium, Bulgaria, Denmark, Estonia, Finland, France, Germany, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Portugal, Sweden and Slovenia.
The UK’s wish of re-joining the Lugano Convention, have been dented by the EU’s unusual recommendation for the member states not consent to the UK’s accession application. EU’s Council will issue a final decision but the member states are not all aligned.
The Enlarged Board of Appeal issued a decision G1/19 holding that current EPO case law on computer-implemented inventions (COMVIK approach – T641/00) also applies to computer-implemented simulations as the present invention.
In principle, a patent application for a technical invention must be filed at a patent office before the invention has been made available to the public.
On the 20 July 2020, the Preparatory Committee of the Unified Patent Court (UPC) published UK Withdrawal from the UPCA, stating that “A deposit of the withdrawal notification of ratification has been deposited with the Council Secretariat” after Amanda Solloway (UK IP Minister) parliamentary written statement in the House of Commons.
The UK Supreme Court has overturned a decision from the Court of Appeal to find two of Regeneron’s transgenic mouse EP/UK patents invalid because they were insufficient. This judgement has returned the bar on sufficiency requiring support for practically every embodiment.
The answer is ‘certainly yes‘ – provided, however, the product or formulation is new, inventive and has a technical character.
Although the patent laws of other countries contain similar patentability requirements, few patent offices are as strict in applying this as the EPO. According to the EPO, any amendments to the claims must be directly and unambiguously derivable from the application as originally filed.
